Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus vector-based gene therapy designed to deliver a functional copy of the *F9* gene for the treatment of Hemophilia B. It is a one-time intravenous infusion that facilitates the endogenous production of Factor IX.
## Primary Indications
Treatment of adults with moderately severe to severe hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is 5 × 10¹¹ vector genomes per kilogram (vg/kg) administered as a single intravenous infusion.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Use in the pediatric population is not currently indicated.
## Dose Adjustments
No dose adjustments are provided for renal or hepatic impairment. Dosage is strictly calculated based on baseline body weight.
## Contraindications
There are no formal contraindications listed in the FDA label. However, it is not recommended for patients with pre-existing neutralizing antibodies to AAVRh74 variant, as determined by a validated specialized assay.
## Adverse Effects
Common adverse reactions include increased liver enzymes (ALT/AST), infusion-related reactions (nausea, fatigue, pyrexia), headache, and an increase in local inflammatory response.
## Key Drug Interactions
No formal drug-drug interaction studies have been performed. Corticosteroids are required as part of the premedication and post-infusion regimen to manage potential immune responses and liver enzyme elevations; therefore, interactions related to systemic glucocorticoid use (e.g., CYP3A4 substrates, NSAIDs, anticoagulants) must be monitored.
## Monitoring
* **Liver Enzymes:** Monitor ALT/AST levels weekly for at least the first 3 months post-infusion to detect and manage immune-mediated hepatotoxicity.
* **Factor IX Activity:** Monitor plasma Factor IX activity levels periodically to assess sustained therapeutic response.
* **Bleeding Events:** Monitor for clinical signs of hemorrhage despite treatment.
## Clinical Pearls
* **Immune Management:** Use of prophylactic corticosteroids (tapered over several weeks) is mandatory to prevent or mitigate the immune-mediated reduction in transgene expression caused by liver inflammation.
* **Baseline Testing:** Patients must be screened for anti-AAVRh74 neutralizing antibodies via a validated assay prior to administration; presence of these antibodies may render the therapy ineffective.
* **Administration:** It must be prepared and infused under the supervision of a healthcare provider experienced in the treatment of hemophilia. The infusion rate should be slowed or interrupted if infusion-related reactions occur.
***
**Educational Disclaimer:** This information is for educational purposes only. Dosage, indications, and safety information are subject to change based on evolving clinical data and manufacturer updates. Always verify current prescribing information, institutional protocols, and FDA-approved labeling prior to prescribing or administering this medication.
